Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | MME | P08473 | 3/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595205 | 0.87 | AQP1 (0.37) | AQP1MMEKMT2A | |
| SCHEMBL4224650 | 0.87 | MME (0.41) | PPARGPPARAMMECAPN1KMT2A | |
| SCHEMBL6373731 | 0.86 | AQP1 (0.47) | AQP1PPARGPPARAMAPT | |
| SCHEMBL4596622 | 0.86 | AQP1 (0.56) | AQP1PPARGPPARAMMECAPN1 | |
| SCHEMBL4229676 | 0.83 | PPARG (0.38) | AQP1PPARGPPARAMMECAPN1 | |
| SCHEMBL6374679 | 0.81 | AQP1 (0.38) | AQP1CAPN1KMT2AL3MBTL1MAPT | |
| SCHEMBL4597134 | 0.79 | AQP1 (0.51) | AQP1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL4596685 | 0.79 | POLB (0.37) | PPARGPPARAKMT2AL3MBTL1MAPT | |
| SCHEMBL4596608 | 0.78 | MMEL1 (0.39) | AQP1CAPN1MAPTALDH1A1 | |
| SCHEMBL4595337 | 0.78 | PTGS2 (0.38) | AQP1CAPN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | AQP1 2290/4885PPARG 1956/4885PPARA 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.